Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Blood (2024) 144 (18): 1951–1961.

https://doi.org/10.1182/blood.2024024761

Published: 2024

Includes: Supplemental data

Journal Articles

Analysis of Clinical Features, Prognostic Characteristics and Gene Mutations of the EB Subtype of Primary Myelodysplastic Syndrome Patients with Myelofibrosis

Gaixiang Xu, Wei Wang, Shuanghong Zhu, Kongfei Li, Xinping Zhou, Liya Ma, Li Ye, Chen Mei, Lu Wang, Lingxu Jiang, Haitao Meng, Wen-Juan Yu, Jie Jin, Hongyan Tong, Jian Huang

Blood (2023) 142 (Supplement 1): 6481.

https://doi.org/10.1182/blood-2023-184789

Published: 2023

Journal Articles

Single-Cell Sequencing Reveals a Close Correlation between the Number of MDSCs and the Gene Expression Levels of GPX1 and S100A8/S100A9 in Patients with Myelofibrosis

Qiutian Feng, Shiwei Hu, Danhong Xiang, Xinlu Zhang, Lingrong Tu, Jian Huang

Blood (2023) 142 (Supplement 1): 6342.

https://doi.org/10.1182/blood-2023-184791

Published: 2023

Journal Articles

Comparison of Characteristics of Chronic Myeloid Leukemia Combined with Different Degrees of Myelofibrosis : A Real-World Multicenter Retrospective Study from China

Xinlu Zhang, Xiudi Yang, Jingjing Zhu, Jian Huang

Blood (2023) 142 (Supplement 1): 6357.

https://doi.org/10.1182/blood-2023-184875

Published: 2023

Journal Articles

Risk Factors for Severe Infection and Unfavorable Outcomes in Hematologic Malignancy Patients with COVID-19 Inflection during the Omicron Era: A Chinese Single-Center Retrospective Study

Blood (2023) 142 (Supplement 1): 5384.

https://doi.org/10.1182/blood-2023-184470

Published: 2023

Journal Articles

A Predictive Scoring System for Therapy Failure of Tyrosine-Kinase Inhibitors in Patients with Chronic-Phase Chronic Myeloid Leukemia

Xiao-shuai Zhang, Bingcheng Liu, Jian Huang, Xin Du, Yanli Zhang, Na Xu, Xiaoli Liu, Li Weiming, Hai Lin, Huanling Zhu, Yunfan Yang, Ling Pan, Xiao-jun Huang, Qian Jiang

Blood (2023) 142 (Supplement 1): 3167.

https://doi.org/10.1182/blood-2023-185473

Published: 2023

Journal Articles

Clinical and Genetic Features By Next-Generation Sequencing and RNA Sequencing in Pre-Fibrotic Primary Myelofibrosis Patients

Shiwei Hu, Xiudi Yang, Jingjing Zhu, Jian Huang

Blood (2023) 142 (Supplement 1): 1836.

https://doi.org/10.1182/blood-2023-182703

Published: 2023

Journal Articles

The Upregulation of the FBLN1 and HS3ST4 Genes May Represent a Potential Mechanism Driving the Fibrotic Progression in Primary Myelofibrosis and Leading to Adverse Prognosis

Qiutian Feng, Shiwei Hu, Xinlu Zhang, Jian Huang

Blood (2023) 142 (Supplement 1): 6348.

https://doi.org/10.1182/blood-2023-184842

Published: 2023

Journal Articles

Internal and External Validation of the Predictive Scoring Systems from Essential Thrombocythemia to Post-ET Myelofibrosis

Danhong Xiang, Xiudi Yang, Jingjing Zhu, Jian Huang

Blood (2023) 142 (Supplement 1): 6424.

https://doi.org/10.1182/blood-2023-184890

Published: 2023

Journal Articles

How Induction Cycles before Remission Influence Long-Term Survival in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 6001.

https://doi.org/10.1182/blood-2023-186048

Published: 2023

Journal Articles

Mean Corpuscular Hemoglobin Optimizes the Thrombocytosis Risk Stratification in Polycythemia Vera: A Retrospective Multi-Center Study

Danhong Xiang, Xiudi Yang, Shiwei Hu, Jian Huang

Blood (2023) 142 (Supplement 1): 6427.

https://doi.org/10.1182/blood-2023-185468

Published: 2023

Journal Articles

Combination of Olverembatinib and VP Regimen As First-Line Therapy for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Gaixiang Xu, Yinjun Lou, Huafeng Wang, Wen-Juan Yu, Liping Mao, Jian Huang, Chenying Li, Shanshan Suo, Hongyan Tong, Jie Jin

Blood (2023) 142 (Supplement 1): 4205.

https://doi.org/10.1182/blood-2023-187130

Published: 2023

Journal Articles

Targeted Next-Generation Sequencing Identifies Additional Mutations Other Than BCR-ABL in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study

Shiwei Hu, Chen DAN, Xiaoqiong Zhu, Jian Huang

Blood (2022) 140 (Supplement 1): 9633–9634.

https://doi.org/10.1182/blood-2022-158739

Published: 2022

Journal Articles

Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 9620–9623.

https://doi.org/10.1182/blood-2022-166431

Published: 2022

Journal Articles

A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy

Blood (2022) 140 (Supplement 1): 9637–9639.

https://doi.org/10.1182/blood-2022-168703

Published: 2022

Journal Articles

Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor

Blood (2022) 140 (Supplement 1): 3891–3894.

https://doi.org/10.1182/blood-2022-168812

Published: 2022

Journal Articles

Efficiency and Safety of Avatrombopag in the Management of Thrombocytopenia with TPO or Tpora Ineffective：a Prospective, Single Arm, Exploratory Clinical Study

Shengjie Wang, Xinlu Zhang, Chen DAN, Jian Huang

Blood (2022) 140 (Supplement 1): 8416–8417.

https://doi.org/10.1182/blood-2022-166467

Published: 2022

Journal Articles

Is the 2 nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study

Blood (2022) 140 (Supplement 1): 815–817.

https://doi.org/10.1182/blood-2022-166855

Published: 2022

Journal Articles

Clinical Features and Outcomes of Polycythemia Vera Patients with Different JAK2 V617F Mutational Status and Allele Burden

Lan Zhang, Keyi Jin, Min Yang, Xiaoqiong Zhu, Jian Huang

Blood (2022) 140 (Supplement 1): 12286–12287.

https://doi.org/10.1182/blood-2022-166253

Published: 2022

Journal Articles

Identification and Separation of Distinct Subpopulations of Hematopoietic Stem Cells and Multipotent Progenitors By Deep Learning

Yaling Liu, Jian Huang

Blood (2022) 140 (Supplement 1): 11398.

https://doi.org/10.1182/blood-2022-160391

Published: 2022

NARROW

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Analysis of Clinical Features, Prognostic Characteristics and Gene Mutations of the EB Subtype of Primary Myelodysplastic Syndrome Patients with Myelofibrosis

Single-Cell Sequencing Reveals a Close Correlation between the Number of MDSCs and the Gene Expression Levels of GPX1 and S100A8/S100A9 in Patients with Myelofibrosis

Comparison of Characteristics of Chronic Myeloid Leukemia Combined with Different Degrees of Myelofibrosis : A Real-World Multicenter Retrospective Study from China

Risk Factors for Severe Infection and Unfavorable Outcomes in Hematologic Malignancy Patients with COVID-19 Inflection during the Omicron Era: A Chinese Single-Center Retrospective Study

A Predictive Scoring System for Therapy Failure of Tyrosine-Kinase Inhibitors in Patients with Chronic-Phase Chronic Myeloid Leukemia

Clinical and Genetic Features By Next-Generation Sequencing and RNA Sequencing in Pre-Fibrotic Primary Myelofibrosis Patients

The Upregulation of the FBLN1 and HS3ST4 Genes May Represent a Potential Mechanism Driving the Fibrotic Progression in Primary Myelofibrosis and Leading to Adverse Prognosis

Internal and External Validation of the Predictive Scoring Systems from Essential Thrombocythemia to Post-ET Myelofibrosis

How Induction Cycles before Remission Influence Long-Term Survival in Acute Myeloid Leukemia

Mean Corpuscular Hemoglobin Optimizes the Thrombocytosis Risk Stratification in Polycythemia Vera: A Retrospective Multi-Center Study

Combination of Olverembatinib and VP Regimen As First-Line Therapy for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Targeted Next-Generation Sequencing Identifies Additional Mutations Other Than BCR-ABL in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study

Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia

A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy

Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor

Efficiency and Safety of Avatrombopag in the Management of Thrombocytopenia with TPO or Tpora Ineffective：a Prospective, Single Arm, Exploratory Clinical Study

Is the 2 nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study

Clinical Features and Outcomes of Polycythemia Vera Patients with Different JAK2 V617F Mutational Status and Allele Burden

Identification and Separation of Distinct Subpopulations of Hematopoietic Stem Cells and Multipotent Progenitors By Deep Learning

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only